Astellas Pharma Canada pledges additional funding in support of Canadian National Transplant Research Program

Astellas Pharma Canada pledges additional funding in support of Canadian 
National Transplant Research Program 
Goal is to improve patient health outcomes for organ and tissue transplant 
recipients 
MARKHAM, ON, July 3, 2013 /CNW/ - Astellas Pharma Canada, Inc. has announced a 
new partnership with the recently launched Canadian National Transplant 
Research Program (CNTRP), a novel research initiative that brings a 
collaborative and transdisciplinary approach to advancing research and patient 
care in the field of transplant. 
Astellas has pledged $1 Million over a period of five years to support 
Canadian investigators in the transplant field as they work to address 
barriers to tissue and organ donation, with the ultimate goal of improving 
long-term outcomes and quality of life for transplant patients. 
The program is led byDr. Lori Westat the Alberta Transplant Institute, 
University of Alberta, andDr. Marie-Josée Hébertat the Université de 
Montréal. It brings together 105investigators and 86 collaborators from 
13 different universities and research centres across Canada. 
"By bringing the transplant research community together with industry, we will 
be able to investigate barriers to improve the availability of transplants for 
all patients who need them, to improve the safety of transplants so we can 
have better long-term results and fewer complications, as well as to improve 
the efficacy of transplants so we can improve the quality of life of patients 
who have been transplanted," says Dr. Lori West, Director of the CNTRP and 
Professor of Pediatrics, Surgery and Immunology at the University of 
Alberta. "Industry engagement with the university-based academic researchers 
of the CNTRP will be exceedingly helpful in guiding subsequent innovation by 
engaging basic science and clinical researchers in the continuum of 
discovery. Stronger bridging with industry will accelerate health outcome 
improvements and create an environment for innovation, on which the CNTRP will 
build commercial partnerships towards better health for Canadians." 
The program has the potential to have a transformative effect on the field of 
transplantation. The hope is not only to increase scientific knowledge to 
improve current healthcare practices, but also to drive further research that 
will ultimately translate into novel treatments and enhanced donation policies 
for the future. The CNTRP is the first program in the world to unite and 
integrate the solid organ transplant, bone marrow transplant and the donation 
and critical care research communities together in a groundbreaking national 
research endeavour.(1) 
"Astellas has a proud history of supporting the Canadian transplant 
community," says Michael Tremblay, President, Astellas Pharma Canada, Inc. "We 
are pleased to be able to provide additional support for key research 
activities that will ultimately lead to better outcomes for transplant 
patients here in Canada, and beyond." 
About the Canadian National Transplant Research Program (CNTRP) 
The Canadian National Transplant Research Program (CNTRP) is anational 
initiative designed to increase organ and tissue donation in Canada and 
enhance the survival and quality of life of Canadians who receive transplants. 
The research goals of the CNTRP:​ 


    --  Increase the availability of transplants 
    --  Extend the longevity of grafts 
    --  Improve the long-term survival and quality of life of
        transplant patients 
    --  Develop and enhance the pool of researchers and clinicians in
        the field of transplantation 
    --  Integrate and coordinate transplantation research nationwide

More information about CNTRP can be found at www.cntrp.ca.

About Astellas Pharma Canada, Inc. 
Astellas Pharma Canada, Inc., headquartered in Markham, ON, is a Canadian 
affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical 
company dedicated to improving the health of people around the world through 
the provision of innovative and reliable pharmaceutical products. The 
organization is committed to becoming a global category leader in focused 
areas by combining outstanding R&D and marketing capabilities. In Canada, 
Astellas has an intense commercial focus on five therapeutic areas - Urology, 
Immunology, Infectious Disease, Dermatology and Oncology.

For more information about Astellas Pharma Canada, Inc., please visit the 
corporate website: www.astellas.ca

(_____________________________________________________________________)
(1 )Harper Government supports Canadian National Transplant Research Program. 
Press release, dated April 22, 2013.

Naomi Côté Corporate Communications Astellas Pharma Canada, Inc. (905) 
946-5621 naomi.cote@astellas.com

Dr. Lori West Director, Canadian National Transplant Research Program (780) 
492-3200 loriwest@cntrp.ca

SOURCE: Astellas Pharma Canada, Inc.

To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/July2013/03/c3939.html

CO: Astellas Pharma Canada, Inc.
ST: Ontario
NI: MTC HEA CHARITY 

-0- Jul/03/2013 12:30 GMT


 
Press spacebar to pause and continue. Press esc to stop.